HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

1- butyl- 3- chloro- 4- (4- phenyl- 1- piperidinyl)- (1H)- pyridone

an mGlu2 receptor modulator; structure in first source

Also Known As:

ADX71149; JNJ-40411813

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Pyridones: 14
      - 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone: 4
  - Piperidines: 17
    - 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone: 4

Experts

1.	Bartolomé, José Manuel: 1 article (01/2019)
2.	Cid, José María: 1 article (01/2019)
3.	Trabanco, Andrés A: 1 article (01/2019)
4.	Ceusters, Marc: 1 article (06/2016)
5.	Daly, Ella: 1 article (06/2016)
6.	De Boer, Peter: 1 article (06/2016)
7.	De Smedt, Heidi: 1 article (06/2016)
8.	Drevets, Wayne C: 1 article (06/2016)
9.	Kent, Justine M: 1 article (06/2016)
10.	Kezic, Iva: 1 article (06/2016)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 01/01/2019 - "Negative phase 2 schizophrenia clinical trials with JNJ-40411813 and AZD8529 seem to have tempered the high expectations of the scientific community on the utility of mGlu2 PAMs for the treatment of schizophrenia. " 08/01/2013 - "In schizophrenia, add-on treatments with glycine, D-serine, D-alanine, D-cycloserine, D-amino acid oxidase inhibitors, glycine transporter-1 (GlyT-1) inhibitors (e.g., sarcosine, bitopertin) and agonists (e.g., LY2140023) or positive allosteric modulator (e.g., ADX71149) of group II metabotropic glutamate receptors (mGluRs) have been studied. "
2.	Partial Epilepsies (Epilepsy, Partial) 12/01/2022 - "For adult focal epilepsies, padsevonil and carisbamate are at a more advanced Phase III stage of clinical development followed by compounds at Phase II like selurampanel, XEN1101 and JNJ-40411813. "
3.	Major Depressive Disorder (Major Depressive Disorders) 06/03/2016 - "This phase 2a, randomized, multicenter, double-blind, proof-of-concept study was designed to evaluate, efficacy, safety and tolerability of JNJ-40411813/ADX71149, a novel metabotropic glutamate 2 receptor positive allosteric modulator as an adjunctive treatment for major depressive disorder (MDD) with significant anxiety symptoms. "

Related Drugs and Biologics

1.	AZD8529
2.	Glutamic Acid (Glutamate)
3.	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)
4.	Serine (L-Serine)
5.	Sarcosine (Methylglycine)
6.	Glycine (Aminoacetic Acid)
7.	D-Amino-Acid Oxidase (D-Amino Acid Dehydrogenase)
8.	Cycloserine (Seromycin)
9.	Alanine (L-Alanine)
10.	(4- (3- fluoro- 5- trifluoromethylpyridin- 2- yl)piperazin- 1- yl)(5- methanesulfonyl- 2- (2,2,2- trifluoro- 1- methylethoxy)phenyl)methanone